Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: Is more suppression better? Are pre-injection LH Levels useful in monitoring treatment?

Journal of Pediatric Endocrinology and Metabolism

Volumn 20, Issue 11, 2007, Pages 1189-1198

  Kunz, Gregory J ^a   Sherman, Tami Irwin ^a   Klein, Karen Oerter ^a  

^a RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Estradiol; Leuprolide acetate; Luteinizing hormone; Precocious puberty

Indexed keywords

ESTRADIOL; GONADORELIN; LEUPRORELIN; LUTEINIZING HORMONE;

ADOLESCENT DISEASE; ARTICLE; BIOASSAY; BODY HEIGHT; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG DOSE INCREASE; ESTRADIOL BLOOD LEVEL; FEMALE; GROWTH RATE; HORMONE INHIBITION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; PATIENT MONITORING; PRECOCIOUS PUBERTY;

EID: 37349082475     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2007.20.11.1189     Document Type: Article

References (31)

1. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature N Engl J Med 2003; 348: 908-917.
2. Cutler GB Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J Steroid Biochem Mol Biol 1997; 61: 141-144.
3. Weise M, Flor A, Barnes KM, Cutler GB Jr, Baron J. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J Clin Endocrinol Metab 2004; 89: 103-107.
4. Boepple PA, Crowley WF Jr. Gonadotrophin-releasing hormone agonist treatment of central precocious puberty: an analysis of growth data in a developmental context. Acta Paediatr Scand Suppl 1990; 367: 38-43.
5. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 1994; 94: 2475-2480.
6. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Ed. Stanford, CA: Stanford University Press, 1959.
7. Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A. Height predictions in normal children and in patients with various pathologic conditions. J Pediatr 1978; 93: 749-755.
8. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-4716.
9. Manasco PK, Pescovitz OH, Hill SC, Jones JM, Barnes KM, Hench KD, Loriaux DL, Cutler GB Jr. Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty. J Pediatr 1989; 115: 105-108.
10. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002; 109: e30
11. Brito V, Latronicon A, Arnhold IJP, Mendonca BB. A single leuteinizing hormone detemination 2 hours after depot leuprolide is useful for therapy monitoring of gondadotropin-dependent precocious pubery in girls. J Clin Endocrinol Metab 2004; 89: 4338-4342.
12. Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 1993; 147: 653-657.
13. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, Olney R, Wilson DM. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992; 121: 634-640.
14. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty J Pediatr 1995; 127: 47-52.
15. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long-term treatment with desorelin. J Clin Endocrinol Metab 1991; 73: 1235-1240.
16. Klein KO, Baron J, Barnes KM, Pescovitz OH, Cutler GB Jr. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with an LHRH agonist. J Clin Endocrinol Metab 1998; 83: 2387-2389.
17. Van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002; 87: 506-512.
18. Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004; 17: 759-766.
19. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004; 10: 135-147.
20. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, Wintergerst K, Chi C, Klein KO, Neely EK. Sequential comparisons of 1-month and 3-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006; 91: 1862-1867.
21. Foster CM. Editorial: Does lupron dose make a difference in outcome when treating children with precocious puberty? J Clin Endocrinol Metab 2006; 91: 1667-1668.
22. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosages for sexual precocity. J Clin Endocrinol Metab 1991; 73: 50-52.
23. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics 1996; 97: 517-519.
24. Garibaldi LR, Picco P, Magier S, Chevli R, Aceto T. Serum luteinizing hormone concentrations, as measured by a sensitive immunoradiometric assay, in children with normal, precocious, or delayed pubertal development. J Clin Endocrinol Metab 1991; 72: 888-898.
25. Lee PA. Central precocious puberty: an overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin North Am 1999; 28: 901-918.
26. Lee PA, Page JG; the Leuprolide Study Group. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr 1989; 114: 321-324.
27. Kreiter M, Burstein S, Rosenfield R, Moll GW, Cara JF, Yousefzadeh DK, Cuttler L, Levitsky LL. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990; 117: 364-370.
28. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999; 81: 329-332.
29. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000; 137: 819-825.
30. Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, Argente J, Stene M. Normal ranges for immunochemiluminometric gonaclotropin assays. J Pediatr 1995; 127: 40-46.
31. Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F, Zamboni G, Bernasconi S, et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr 1994; 83: 1052-1056.